TY PHAR.(SZ:002728) 光大证券研究·2026-03-25 23:05Summary of Key Points Core Viewpoint - The company reported strong financial performance for 2025, with significant increases in revenue and net profit, indicating effective marketing reforms and recovery in profitability [4]. Financial Performance - The company achieved operating revenue of 925 million, net profit attributable to shareholders of 82 million, and net profit excluding non-recurring items of 80 million, representing year-on-year increases of 34.4%, 298.5%, and 328.9% respectively [4]. - Operating cash flow reached 244 million, up 1182% year-on-year, with basic EPS at 0.16 yuan [4]. - A cash dividend of 1.5 yuan per 10 shares was proposed, with total cash dividends and share buybacks accounting for 100.74% of the net profit for 2025 [4]. Marketing and Sales Strategy - The company has been implementing ongoing marketing reforms, leading to a steady recovery in sales revenue [5]. - The OTC product line has shifted to a mixed model of self-operated and promotional service providers, with an expanding self-operated team and broader regional coverage [5]. - The cough remedy product saw sales of 636 million pieces, recovering to 63.10% of the same period in 2023, contributing to a strong recovery in profitability [5]. Business Segment Performance - In 2025, revenue from the pharmaceutical industry increased by 35.21%, while pharmaceutical commerce remained stable with a slight decline of 0.03% [6]. - Revenue from traditional Chinese medicine doubled, driven by increased sales of the cough remedy, while chemical drug formulations experienced a decline due to reduced downstream demand [6]. - The company invested 260 million in brand building, a year-on-year increase of 107.7%, enhancing brand recognition, particularly among younger consumers [6].